Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Protara Therapeutics, Inc. (TARA) had Return on Tangible Equity of -10.02% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-13.26M |
|
-- |
|
-- |
|
$14.76M |
|
$-14.76M |
|
$1.50M |
|
$-13.26M |
|
$-13.26M |
|
$-13.26M |
|
$-13.26M |
|
$-13.26M |
|
$-13.26M |
|
$-14.76M |
|
$-14.79M |
|
42.27M |
|
42.27M |
|
$-0.31 |
|
$-0.31 |
|
| Balance Sheet Financials | |
$135.64M |
|
$0.83M |
|
$8.99M |
|
$144.64M |
|
$9.91M |
|
-- |
|
$2.44M |
|
$12.35M |
|
$132.29M |
|
$132.29M |
|
$132.29M |
|
38.59M |
|
| Cash Flow Statement Financials | |
$-39.41M |
|
$-112.58M |
|
$1.75M |
|
$163.54M |
|
$13.30M |
|
$-150.25M |
|
$2.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.69 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-39.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.02% |
|
|
Return on Tangible Equity |
-10.02% |
-9.17% |
|
-10.02% |
|
$3.43 |
|
$-0.93 |
|
$-0.93 |
|